First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium by Balis, Frank M. et al.
1 3
Cancer Chemother Pharmacol (2017) 79:181–187
DOI 10.1007/s00280-016-3220-6
ORIGINAL ARTICLE
First‑dose and steady‑state pharmacokinetics of orally 
administered crizotinib in children with solid tumors: a report 
on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot 
Consortium
Frank M. Balis1 · Patrick A. Thompson2 · Yael P. Mosse1 · Susan M. Blaney3 · 
Charles G. Minard3 · Brenda J. Weigel4,5 · Elizabeth Fox1 
Received: 2 December 2016 / Accepted: 8 December 2016 / Published online: 28 December 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
crizotinib was 731 ± 241 mL/min/m2. Steady-state AUC0–τ 
at 280 mg/m2/dose was 2.5-fold higher than the AUC0–∞ in 
adults receiving 250 mg (~140 mg/m2). Age, sex and drug 
formulation do not account for the inter-subject variability 
in AUC0–τ at steady state. The accumulation index was 4.9, 
and the half-life estimated from the accumulation index 
was 36 h.
Conclusions The pharmacokinetics of oral crizotinib in 
children is similar to that in adults. Steady-state trough-
free crizotinib concentrations in plasma at the MTD exceed 
inhibitory concentrations of crizotinib in ALCL cell lines.
ClinicalTrials.gov identifier NCT00939770.
Keywords Crizotinib · Pharmacokinetics · Childhood 
cancer · Children · ALK
Abbreviations
ALCL  Anaplastic large-cell lymphoma
AUC  Area under the plasma concentration–time curve
C12h  Plasma concentration 12-h post-first dose 
(trough)
C
ss
12h
  Plasma concentration 12-h post-dose (trough) at 
steady state
C
ss
ave
  Average plasma concentration at steady state
CL  Clearance
CL/F  Apparent clearance
Cmax  Peak plasma concentration
C
ss
max  Peak plasma concentration at steady state
F  Fraction of the dose that is absorbed 
(bioavailable)
FC  Formulated capsule
HPLC  High-pressure liquid chromatography
IRT  Immediate-release tablet
MTD  Maximum tolerated dose
NSCLC  Non-small-cell lung cancer
Abstract 
Purpose Characterize the pharmacokinetics of oral crizo-
tinib in children with cancer.
Methods Sixty-four children with solid tumors or ana-
plastic large-cell lymphoma (ALCL) enrolled on a phase 
1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, 
had pharmacokinetic sampling after the first dose (n = 15) 
or at steady state (n = 49). Dose levels studied were 100, 
130, 165, 215, 280 and 365 mg/m2/dose administered twice 
daily. Two capsule and two oral liquid formulations were 
used over the course of the trial. Crizotinib was quantified 
with a validated HPLC/tandem mass spectrometry method 
with a lower limit of detection of 0.2 ng/mL. Pharmacoki-
netic parameters were derived using non-compartmental 
analysis.
Results Time to peak plasma concentration was 4 h. 
At 280 mg/m2 (MTD), mean (±SD) steady-state peak 
plasma concentration was 717 ± 201 ng/mL, and steady-
state trough plasma concentration was 480 ± 176 ng/mL. 
At steady state, AUC0–τ was proportional to dose over the 
dose range of 215–365 mg/m2/dose. Apparent clearance of 
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OS  Oral solution
PIB  Powder in bottle
PIC  Powder in capsule
R  Accumulation index
τ  Dosing interval
T1/2  Half-life
tlast  Time of last measured plasma concentration
Tmax  Time post-dose that the Cmax is reached
Introduction
Crizotinib is a small molecule inhibitor of multiple tyrosine 
kinases, including the anaplastic lymphoma kinase encoded 
by the ALK gene, hepatocyte growth factor receptor (c-met) 
encoded by MET and the tyrosine kinase, ROS encoded by 
ROS1 [1]. Crizotinib is approved worldwide for the treat-
ment of the subset of non-small-cell lung cancers (NSCLC) 
with rearrangements involving ALK [2–4]. Responses to 
crizotinib have also been reported in patients with anaplas-
tic large-cell lymphoma (ALCL) and inflammatory myofi-
broblastic tumors [5, 6], both of which have a high inci-
dence of ALK rearrangements, especially in children [7].
The adult recommended oral dose of crizotinib is 250 mg 
twice daily, which is equivalent to approximately 140 mg/
m2/dose. The pharmacokinetics of crizotinib in adults 
has been studied after a single dose and at steady state 
(≥15 days) in patients with NSCLC using 250-mg formu-
lated capsules and after a single 50-mg dose of an experi-
mental intravenous formulation or a single 250-mg dose of 
three oral formulations [formulated capsules (FC), powder 
in capsules (PIC) and immediate-release tablets (IRT)] in 
healthy volunteers [8, 9]. The mean (C.V.) clearance (CL) 
of crizotinib was 47 (18%) L/h, the volume of distribution at 
steady state was 1770 (18%) L and the half-life (T1/2) was 39 
(16%) h, following the intravenous dose. The absolute bio-
availability (F) of the IRT formulation was 43%. After oral 
administration, the time to peak concentration (Tmax) was 
5 h, the peak plasma concentration (Cmax) was 120–135 ng/
mL, and the area under the plasma concentration–time curve 
extrapolated to infinity (AUC0–∞) was 2700–2900 ng h/mL. 
The three oral formulations were bioequivalent. The accu-
mulation index (R) at steady state was 4.5.
A separate phase 1/2 trial of oral crizotinib adminis-
tered twice daily using PIC, FC and two liquid formula-
tions was conducted in children with solid tumors and 
ALCL [6]. Dose levels studied were 100, 130, 165, 215, 
280 and 365 mg/m2/dose, and the maximum tolerated dose 
(MTD) was 280 mg/m2/dose, which is twofold higher than 
the adult recommended dose. Steady-state pharmacoki-
netic parameters in 18 children receiving 280 mg/m2/dose 
were briefly summarized in the previously reported phase 
1/2 trial results [6]. This report describes in more detail the 
pharmacokinetics of crizotinib in children enrolled on the 
phase 1/2 trial and includes 64 subjects treated at the six 
dose levels and studied after the first dose (n = 15) or at 
steady state (n = 49). The previously reported 18 patients 
are included in this cohort.
Materials and methods
Drug
Crizotinib was provided by Pfizer Inc. (New York, NY) in 
four formulations over the course of the phase 1/2 clinical 
trial:
•	 PIC in 10, 50 and 100 mg strengths,
•	 FC (commercial formulation) in 150, 200 and 250 mg 
strengths,
•	 Powder in bottles (PIB) containing 2500 mg in a 4 oz 
vial that is reconstituted to a 25 mg/mL suspension,
•	 Oral solution (OS) containing 25 mg/mL in a sweetened 
and flavored aqueous vehicle. OS replaced PIB.
The OS is bioequivalent to FC in adults (Pfizer, data on file).
Study design
The pediatric phase 1/2 trial of crizotinib (ADVL0912) was 
sponsored by Pfizer Inc. and conducted within the twenty-
one member institutions of the Pediatric Phase 1 and Pilot 
Consortium plus five additional sites. The protocol was con-
ducted in accordance with the Declaration of Helsinki and 
approved by the Institutional Review Boards at all participat-
ing institutions. Informed consent was obtained from all sub-
jects who were 18 years or older or from the parents of sub-
jects under the age of 18 years. The eligibility criteria, trial 
design and subject cohorts have been previously reported 
[6]. Crizotinib was administered orally, twice daily, continu-
ously at doses of 100, 130, 165, 215, 280 and 365 mg/m2/
dose on the phase 1 dose escalation portion of the trial and 
at a dose of 280 mg/m2/dose after this dose was identified as 
the MTD. For this report, the administered dose per m2 was 
calculated by dividing the patient’s dose (in mg) that was 
determined by a dosing nomogram in the protocol by their 
body surface area. In subjects receiving capsules, the admin-
istered dose per m2 often deviated slightly from the dose 
level because of dosing limitations imposed by capsule size.
Sample collection and processing
Subjects studied after their first dose of crizotinib had 2 mL 
blood samples collected into potassium EDTA-containing 
tubes prior to the dose and 0.5, 1, 2, 4, 6, 8 and 24 h after 
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the morning dose. The evening dose of crizotinib was not 
administered on day 1 in these subjects. A trough blood 
sample was also drawn prior to the morning dose on day 7. 
Subjects studied at steady state (day 15–28 of cycle 1) had 
blood samples drawn prior to their first dose on day 1, prior 
to the morning dose at steady state and then 1, 2, 4, 6–8 h 
after the morning dose. Blood samples were protected from 
light and placed on ice. Plasma was separated by centrifu-
gation at 1700g for 10 min at 4 °C and immediately frozen 
at −20 to −70 °C until assayed.
Crizotinib assay
Plasma concentrations of crizotinib were quantified by 
Covance Bioanalytical Services (Indianapolis, IN) using a 
previously described, validated high-pressure liquid chro-
matography (HPLC), tandem mass spectroscopic method 
with a lower limit of quantification of 0.2 ng/mL [8].
Pharmacokinetic analysis
Crizotinib plasma concentration–time data were analyzed 
using model-independent methods. The area under the cri-
zotinib plasma concentration–time curve to the last meas-
ured time point (AUC0–tlast) was derived using the linear 
trapezoidal rule. The limited sampling duration did not 
allow for accurate estimation of the terminal slope of the 
plasma concentration–time curve after the first dose. As 
a result, the terminal T1/2 could not derived, and the AUC 
could not be accurately extrapolated to infinity (AUC0–∞) 
in the subjects studied after the first dose. For calculat-
ing the steady-state AUC over the 12-h dosing interval 
(τ), which is equivalent to AUC0–∞ after a single dose, the 
trough concentration drawn prior to the dose was also used 
as the 12-h post-dose concentration. The average plasma 
crizotinib concentration at steady state (Css
ave
) was derived 
by dividing the AUC0–τ by τ (12 h), and the apparent clear-
ance (CL/F) of crizotinib is the dose divided by AUC0–τ.
R was derived by dividing the day 7 steady-state trough 
concentration (Css
12h
) by the concentration 12 h after the first 
dose (C12h). C12h was estimated by extrapolation using the 
slope estimated from the Ln transformed 8 and 24 h plasma 
concentrations. T1/2 was estimated from the mean R by 
rearranging the equation for calculating R from the T1/2:
Statistical analysis
A linear multiple regression model was used to assess 
the relationship between AUC0–τ normalized to the 
R =
1
1− e
�
−
0.693
t1/2
·τ
�

.
administered dose/m2 at steady state and age, gender and 
drug formulation using the lm function in R statistical soft-
ware package (The R Foundation for Statistical Comput-
ing, http://www.R-project.org).
Results
Subjects
Seventy-five subjects had pharmacokinetic blood sam-
ples drawn after their first dose of crizotinib (n = 15) or 
at steady state immediately prior to and after their morning 
dose (n = 60). The data from 11 subjects studied at steady 
state were not evaluable because the trough sample was not 
drawn at the appropriate time (n = 6), samples were missed 
(n = 2), the dose of crizotinib had been reduced for prior 
toxicity (n = 1), the dose was spit out (n = 1), or the pre-
ceding evening dose had not been given (n = 1). The char-
acteristics of the 64 subjects with evaluable data are listed 
in Table 1.
First‑dose pharmacokinetics
Figure 1 shows the mean plasma crizotinib concentra-
tion–time profiles for subjects studied after the first dose 
at four dose levels, and Table 2 provides the pharmacoki-
netic parameters. Figure 2 shows the relationship of dose 
to AUC0–tlast. AUC0–tlast does not appear to increase in 
proportion to the dose over the twofold dose range (100–
215 mg/m2). This may reflect the substantial inter-subject 
Table 1  Subject characteristics
a One subject received a combination of powder in capsule and pow-
der in bottle
First dose Steady state
Number 15 49
Median (range) age (year) 11.9 (5.7–21.4) 10.1 (2.6–22)
Male/female 10:5 23:26
Dose level (mg/m2/dose)
 100 3
 130 3
 165 7 1
 215 2 5
 280 36
 365 7
Formulation
 Powder in capsule 14 28a
 Powder in bottle 1 8
 Formulated capsule 9
 Oral solution 4
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variability (C.V. for the AUC0–tlast normalized to the admin-
istered dose per m2 was 105%), as well as the small cohort 
size and the influence of an outlier at 130 mg/m2/dose 
(Fig. 2). The mean R across the four dose levels was 4.9, 
and the T1/2 of crizotinib estimated from the mean R was 
36 h.
Steady‑state pharmacokinetics
The crizotinib plasma concentration–time profile over the 
12-h dosing interval at steady state for the dose levels rang-
ing from 165 to 365 mg/m2 is shown in Fig. 1, and the 
mean (±SD) steady-state pharmacokinetic parameters are 
listed in Table 3. At steady state, the increase in AUC0–τ 
is dose-proportional over the narrow dose range (215 to 
365 mg/m2). The variability appears to be lower at steady 
state (C.V. for the AUC0–τ normalized to the administered 
dose per m2 was 30%) than after the first dose. The mean 
(±SD) CL/F of crizotinib after oral dosing in children was 
731 ± 241 mL/min/m2. The ratio of the steady-state peak 
plasma concentration (Cssmax) to C
ss
12h
 at the 280 mg/m2 
dose level (n = 36) was 1.6 ± 0.5, which reflects the intra-
subject variation in plasma crizotinib concentrations over 
the dosing interval at steady state.
A multiple regression analysis evaluating the impact of 
age, gender and drug formulation on the AUC0–τ normal-
ized to the administered dose per m2 at steady state in 49 
subjects demonstrated that these characteristics did not 
account for the variability in AUC0–τ (multiple R
2 = 0.11; 
p = 0.40). Figure 3 shows the relationship between the nor-
malized AUC0–τ and age, gender and drug formulation.
Discussion
We characterized the pharmacokinetics of orally adminis-
tered crizotinib in children after the first dose and at steady 
state (≥14 days of continuous twice daily dosing), at 6 
Fig. 1  Plasma concentration–time profiles in subjects studied after the first dose and at steady state at 6 dose levels. Points are the geometric 
mean and error bars are the SD
Table 2  Pharmacokinetic parameters for oral crizotinib studied after the first dose in children with solid tumors or ALCL at four dose levels 
ranging from 100 to 215 mg/m2/dose
Fourteen of the 15 subjects received the PIC formulation. Values represent the mean ± SD
Dose level (mg/m2/dose) Number of subjects Cmax (ng/mL) Tmax (h) AUC0–tlast (ng h/mL) R
100 3 144 ± 97 3.3 ± 2.2 1260 ± 320 2.8 ± 1.6
130 3 236 ± 217 4.7 ± 1.1 3300 ± 3913 5.8 ± 2.9
165 7 145 ± 70 3.7 ± 2.4 1208 ± 558 5.2 ± 2.1
215 2 196 ± 60 4.0 ± 0 2820 ± 1890 5.0 ± 2.3
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dose levels ranging from 100 to 365 mg/m2/dose using four 
drug formulations. Crizotinib was dosed based on body 
surface area using a dosing nomogram. Despite differences 
in study design and sampling times, the pharmacokinetics 
of crizotinib in children appears to be similar to adults. The 
CL/F of crizotinib in adults was 850 mL/min/m2 after a sin-
gle fixed 250-mg dose in healthy volunteers and 600 mL/
min/m2 at steady state in adults with NSCLC [8, 9]. These 
values are comparable to the mean CL/F at steady state 
in children of 730 mL/min/m2. The Cssmax in adults with 
NSCLC and children is also comparable when adjusted for 
differences in the dose.
Blood sampling after a single oral 250-mg dose of cri-
zotinib in healthy volunteers extended to 144 h, which 
allows for an accurate determination of the 35 h terminal 
T1/2 [8]. It is not feasible to withhold crizotinib dosing for 
6 d to allow for extended blood sampling in children with 
cancer, and estimating the T1/2 from the samples collected 
over 24 h yields a mean T1/2 of 11 h, which is an under-
estimation of the true T1/2 rather than a true difference in 
the disposition of crizotinib in children versus adults. The 
R calculated from the C12h after the first dose and the day 7 
trough concentration in children was 4.9, which is similar 
to 4.5 in adult [9], and the T1/2 estimated from the mean R 
in children was 36 h, which is similar to the T1/2 in adult 
healthy volunteers. Although this is an indirect method of 
estimating the T1/2, it is likely to be more accurate than esti-
mating it directly from the concentration–time curve after 
the first dose because of the limited sampling duration.
At the MTD (280 mg/m2/dose) of crizotinib in children, 
the mean (±SD) Css
ave
 is 580 (±170) ng/mL, and the mean 
C
ss
12h
 is 480 (±180) ng/mL. Plasma protein binding of cri-
zotinib in adults is 90% [9], and free Css
ave
 and Css
12h
 are esti-
mated to be 60 and 50 ng/mL, respectively. These free drug 
concentrations exceed the 10 ng/mL IC50 of crizotinib in 
ALCL cell lines, Karpas299 and SU-DHL-1 that express 
the NPM-ALK fusion protein [10], consistent with the high 
objective response rate to crizotinib in children with ALCL 
treated on the phase 1/2 trial even at doses below the MTD 
[6].
Fig. 2  Relationship between AUC to the last measured time point (24 h) for subjects studied after the first dose or AUC over the 12-h dosing 
interval at steady state and the administered dose of oral crizotinib normalized to subject’s body surface area
Table 3  Pharmacokinetic parameters for oral crizotinib studied at steady state in children with solid tumors or ALCL at four dose levels ranging 
from 165 to 365 mg/m2/dose
Values represent the mean ± SD
Dose level (mg/m2/dose) Number of subjects Cmax (ng/mL) Tmax (h) AUC0–τ (ng h/mL) C
ss
ave
 (ng/mL) CL/F (mL/min/m2) Css
12h
 (ng/mL)
165 1 294 6 2950 246 735 205
215 5 601 ± 118 4.0 ± 1.4 5630 ± 1370 469 ± 114 652 ± 159 354 ± 133
280 36 717 ± 201 3.8 ± 1.7 6990 ± 2080 582 ± 173 736 ± 255 480 ± 176
365 7 972 ± 210 2.1 ± 0.1 8770 ± 2740 731 ± 228 731 ± 223 650 ± 330
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The lactam metabolite of crizotinib, PF-06260182, is 
measurable in plasma, but at substantially lower concen-
trations than the parent drug [8]. Although PF-06260182 is 
active, it is considerably less potent than crizotinib, and it is 
not thought to contribute significantly to the in vivo activ-
ity of crizotinib [9, 11]. For this reason, we did not monitor 
PF-06260182 plasma concentrations in children.
In summary, the pharmacokinetics of oral crizotinib in 
children is similar to that in adults. A more palatable for-
mulation is currently being evaluated in children. Clinical 
trials of crizotinib alone and in combination with chemo-
therapy in children with neuroblastoma, other solid tumors 
and ALCL are ongoing.
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